PPA
SLNO

Parametric Portfolio Associates’s Soleno Therapeutics SLNO Stock Holding History

Parametric Portfolio Associates’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-755
Closed -$28K – 4022
2020
Q3 		$28K Buy
+755
New +$22.1K ﹤0.01% 3901

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Parametric Portfolio Associates's SLNO Position: Q4 2020 in Review

Parametric Portfolio Associates sold out of Soleno Therapeutics (SLNO) in Q4 2020, closing a stake of 755 shares — an estimated $28K sold.

Parametric Portfolio Associates first reported a position in SLNO in Q3 2020 and held it in 1 quarter. The position peaked at $28K in Q3 2020. 67 funds tracked by Wall St. Rank hold SLNO as of Q4 2020.

  • Parametric Portfolio Associates reported no remaining Soleno Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Parametric Portfolio Associates sold 755 Soleno Therapeutics shares in Q4 2020, an estimated $28K.
  • Parametric Portfolio Associates first reported a position in Soleno Therapeutics in Q3 2020 and held it in 1 quarter.
  • Parametric Portfolio Associates's Soleno Therapeutics position peaked at $28K in Q3 2020.
  • 67 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2020.

Based on Parametric Portfolio Associates's 13F filing for Q4 2020, filed 12 Feb 2021.